Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients

Persistence of Solifenacin Treatment in Overactive Bladder Patients in Real Life Practice: A 12-month, Prospective, Multicenter, Open-label, Observational Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00985387

Enrollment

1215

Registered

2009-09-28

Start date

2009-08-31

Completion date

2011-08-31

Last updated

2011-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder, Urinary Bladder, Overactive

Keywords

Solifenacin, Overactive bladder, persistency of the treatment, Vesicare

Brief summary

The purpose of the study is to assess patient's persistency in maintaining solifenacin treatment for overactive bladder.

Interventions

DRUGSolifenacin

oral

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Overactive bladder symptoms lasting for more than 3 months * The question 3 score of the overactive bladder symptom score(OABSS)≥ 2 and the sum score of OABSS ≥ 3 * Symptoms of urinary urgency defined as a level of 1 to 2 in a 3-point Urgency Perception Scale (UPS)

Exclusion criteria

* Any condition that would contraindicate their usage of anticholinergic treatment, including: urinary retention, gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis * Symptomatic acute urinary tract infection (UTI) * Diagnosed or suspected of interstitial cystitis * Treatment with anticholinergic drugs for over 3 months within 12 months prior to the study * Pregnant or nursing women * Treatment within the 14 days before the study or expected to initiate treatment during the study with any anticholinergic drugs other than solifenacin or treatment for overactive bladder with other drugs * Any other condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion

Design outcomes

Primary

Measure	Time frame
percentage of patients who are maintaining solifenacin treatment	Month 0, Month 1, Month 3, Month 6, Month 9 and Month 12

Secondary

Measure	Time frame
percentage of patients who discontinued solifenacin treatment	Month 0, Month 1, Month 3, Month 6, Month 9 and Month 12
percentage of patients who switched to other OAB medication	Month 0, Month 1, Month 3, Month 6, Month 9 and Month 12

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026